{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:55:00Z","timestamp":1793202900237,"version":"4.5.0"},"reference-count":112,"publisher":"American Medical Association (AMA)","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:sec id=\"ab-jrv260008-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Hepatitis B virus (HBV) infection affects an estimated 254 million people worldwide and causes approximately 1.1 million deaths annually. In 2022, there were approximately 1.2 million new HBV infections worldwide and 14\u202f000 in the US.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv260008-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>HBV is a DNA virus transmitted through percutaneous or mucosal exposure to infected blood, semen, or body fluids. Mother-to-child transmission, which is the principal cause of chronic HBV infection globally, occurs in 70% to 90% of infants born to mothers who are hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive and in 5% to 20% of those born to HBsAg-positive\/HBeAg-negative mothers. However, HBV vaccination and administration of hepatitis B immune globulin within 12 to 24 hours of birth prevent approximately 94% of perinatal infections, and adding antiviral therapy in pregnant women with high HBV DNA reduces transmission to less than 1%. Although universal birth-dose HBV vaccination is the most effective strategy for eliminating HBV infection, global birth-dose HBV vaccine coverage was only 45% in 2024. The risk of developing chronic infection (HBsAg positive for more than 6 months) is 90% if HBV infection occurs during infancy, 30% in children aged 1 to 5 years, and less than or equal to 5% in immunocompetent adolescents and adults. HBV infection is diagnosed by serologic testing: HBsAg indicates ongoing infection, antibody to HBsAg indicates immunity, and antibody to hepatitis B core antigen indicates ongoing or past infection. Serum HBV DNA levels quantify virus-replication activity. Assessment of liver inflammation and fibrosis with alanine aminotransferase (ALT) and noninvasive tests such as Fibrosis-4 index and liver elastography guide treatment decisions. Chronic HBV infection may progress to cirrhosis and hepatocellular carcinoma (HCC); the 5-year cumulative risk of cirrhosis is 8% to 15% in untreated chronic HBV infection, and annual HCC incidence is 3% to 5% among patients with cirrhosis. Antiviral therapies\u2014pegylated interferon alfa and nucleos(t)ide analogues (entecavir or tenofovir)\u2014suppress HBV DNA replication and reduce the risk of HCC by approximately 50%. Antiviral treatment is recommended for all patients with chronic HBV and cirrhosis and for those without cirrhosis who have high HBV DNA with elevated ALT or\u2009significant inflammation\/fibrosis. Patients at high risk of HCC should undergo surveillance with ultrasonography and alpha-fetoprotein testing every 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv260008-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>HBV infection causes approximately 1.1 million deaths annually worldwide. Universal HBV vaccination, particularly birth-dose administration, is the most effective strategy to prevent HBV infection. Among patients with HBV infection, antiviral therapy decreases progression to cirrhosis and liver failure and reduces the risk of HCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2026.6070","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T16:30:16Z","timestamp":1777912216000},"page":"1879","source":"Crossref","is-referenced-by-count":12,"title":["Hepatitis B"],"prefix":"10.1001","volume":"335","author":[{"given":"Wen-Juei","family":"Jeng","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Main Branch, Taoyuan, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry Cheuk-Fung","family":"Yip","sequence":"additional","affiliation":[{"name":"Medical Data Analytics Centre, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong"},{"name":"Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna S.","family":"Lok","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"jrv260008r1","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/clinids\/20.4.992","article-title":"Risks of chronicity following acute hepatitis B virus infection: a review.","volume":"20","author":"Hyams","year":"1995","journal-title":"Clin Infect Dis"},{"issue":"1","key":"jrv260008r2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6701a1","article-title":"Prevention of hepatitis B Virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices.","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Recomm Rep"},{"issue":"8219","key":"jrv260008r3","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/S0140-6736(81)92877-4","article-title":"Survival of hepatitis B virus after drying and storage for one week.","volume":"1","author":"Bond","year":"1981","journal-title":"Lancet"},{"issue":"5","key":"jrv260008r7","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021410","article-title":"Hepatitis B virus epidemiology.","volume":"5","author":"MacLachlan","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"10381","key":"jrv260008r8","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B.","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"jrv260008r9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1056\/NEJMra2211764","article-title":"New approaches to chronic hepatitis B.","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N Engl J Med"},{"issue":"50","key":"jrv260008r10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000027941","article-title":"Distribution of hepatitis B virus genotypes and subgenotypes: a meta-analysis.","volume":"100","author":"Liu","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"jrv260008r11","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s12072-024-10648-8","article-title":"Predictors of HBsAg seroclearance in patients with chronic HBV infection treated with pegylated interferon-a: a systematic review and meta-analysis.","volume":"18","author":"Jiang","year":"2024","journal-title":"Hepatol Int"},{"issue":"5","key":"jrv260008r12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/apt.12207","article-title":"Meta-analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma.","volume":"37","author":"Wong","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"jrv260008r13","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1002\/hep.32065","article-title":"HBV genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for HCC: the Hepatitis B Alaska Study.","volume":"74","author":"McMahon","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"jrv260008r14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","article-title":"Immunobiology and pathogenesis of hepatitis B virus infection.","volume":"22","author":"Iannacone","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"jrv260008r15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/liv.12749","article-title":"HBV and the immune response.","volume":"35","author":"Ferrari","year":"2015","journal-title":"Liver Int"},{"key":"jrv260008r16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev.iy.13.040195.000333","article-title":"Hepatitis B virus immunopathogenesis.","volume":"13","author":"Chisari","year":"1995","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"jrv260008r17","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","article-title":"Mechanisms of HBV-induced hepatocellular carcinoma.","volume":"64","author":"Levrero","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"jrv260008r18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/v13020210","article-title":"Hepatitis B virus DNA integration and clonal expansion of hepatocytes in the chronically infected liver.","volume":"13","author":"Mason","year":"2021","journal-title":"Viruses"},{"key":"jrv260008r19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3851\/IMP1621","article-title":"The natural history of chronic HBV infection and geographical differences.","volume":"15","author":"Liaw","year":"2010","journal-title":"Antivir Ther"},{"issue":"1","key":"jrv260008r20","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/HEP.0000000000001354","article-title":"Increased risk of HCC in HBeAg-negative indeterminate phase compared with HBeAg-negative chronic infection.","volume":"83","author":"Hui","year":"2026","journal-title":"Hepatology"},{"issue":"3","key":"jrv260008r21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis.","volume":"156","author":"Yeo","year":"2019","journal-title":"Gastroenterology"},{"issue":"2","key":"jrv260008r23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1365-2893.2005.00581.x","article-title":"Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States.","volume":"12","author":"Wai","year":"2005","journal-title":"J Viral Hepat"},{"issue":"1","key":"jrv260008r24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/hep.1840070106","article-title":"Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients.","volume":"7","author":"Liaw","year":"1987","journal-title":"Hepatology"},{"issue":"1","key":"jrv260008r25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0168-8278(90)90069-4","article-title":"Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection: incidence, predisposing factors and etiology.","volume":"10","author":"Lok","year":"1990","journal-title":"J Hepatol"},{"issue":"2","key":"jrv260008r26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3350\/cmh.2019.0060","article-title":"The dilemma of differentiating between acute hepatitis B and chronic hepatitis B with acute exacerbation: is quantitative serology the answer?","volume":"26","author":"Lall","year":"2020","journal-title":"Clin Mol Hepatol"},{"issue":"9","key":"jrv260008r27","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1016\/j.cgh.2020.01.018","article-title":"Hepatitis flares are associated with better outcomes than no flare in patients with decompensated cirrhosis and chronic hepatitis B virus infection.","volume":"18","author":"Chang","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"jrv260008r28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.14309\/ajg.0000000000001575","article-title":"Hepatitis B virus infection and extra-hepatic manifestations: a systemic disease.","volume":"117","author":"Cacoub","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"jrv260008r29","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/infdis\/143.6.803","article-title":"IgM antibody to hepatitis B core antigen as a diagnostic parameter of acute infection with hepatitis B virus.","volume":"143","author":"Lemon","year":"1981","journal-title":"J Infect Dis"},{"issue":"3","key":"jrv260008r30","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s12072-009-9140-3","article-title":"HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B.","volume":"3","author":"Liaw","year":"2009","journal-title":"Hepatol Int"},{"issue":"7","key":"jrv260008r31","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/gutjnl-2018-317593","article-title":"Advances in non-invasive assessment of hepatic fibrosis.","volume":"69","author":"Loomba","year":"2020","journal-title":"Gut"},{"issue":"1","key":"jrv260008r32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/HEP.0000000000000845","article-title":"AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis.","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"issue":"3","key":"jrv260008r33","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/MOG.0000000000000621","article-title":"The utility of liver biopsy in 2020.","volume":"36","author":"Khalifa","year":"2020","journal-title":"Curr Opin Gastroenterol"},{"issue":"2","key":"jrv260008r34","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"issue":"4","key":"jrv260008r35","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S2468-1253(24)00437-0","article-title":"Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: a systematic review and meta-analysis.","volume":"10","author":"Liguori","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"jrv260008r36","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol Int"},{"issue":"6","key":"jrv260008r37","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"jrv260008r38","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma.","volume":"82","author":"European Association for the Study of the Liver","year":"2025","journal-title":"J Hepatol"},{"issue":"4","key":"jrv260008r39","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J Hepatol"},{"issue":"1","key":"jrv260008r41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"issue":"4","key":"jrv260008r42","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"jrv260008r43","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1097\/HEP.0000000000001549","article-title":"AASLD ISDA Practice Guideline on treatment of chronic hepatitis B.","volume":"83","author":"Ghany","year":"2026","journal-title":"Hepatology"},{"issue":"2","key":"jrv260008r44","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection.","volume":"83","author":"European Association for the Study of the Liver","year":"2025","journal-title":"J Hepatol"},{"issue":"5","key":"jrv260008r46","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1097\/HEP.0000000000000431","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.","volume":"78","author":"Ghany","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"jrv260008r47","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.14218\/JCTH.2023.00320","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022).","volume":"11","author":"You","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"jrv260008r48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2024.105711","article-title":"A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir.","volume":"174","author":"Lumley","year":"2024","journal-title":"J Clin Virol"},{"issue":"10","key":"jrv260008r49","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1111\/liv.14155","article-title":"Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.","volume":"39","author":"Marcellin","year":"2019","journal-title":"Liver Int"},{"issue":"10","key":"jrv260008r50","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"issue":"23","key":"jrv260008r51","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv260008r52","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11-12","key":"jrv260008r53","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/apt.18278","article-title":"Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: final results from two randomised phase 3 trials.","volume":"60","author":"Buti","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"jrv260008r54","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00535-018-1502-y","article-title":"Long-term outcome of entecavir treatment of nucleos(t)ide analogue-na\u00efve chronic hepatitis B patients in Japan.","volume":"54","author":"Suzuki","year":"2019","journal-title":"J Gastroenterol"},{"issue":"10","key":"jrv260008r55","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.","volume":"354","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv260008r56","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"jrv260008r57","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.cgh.2022.08.021","article-title":"The role of off-therapy viral kinetics in the timing and severity of flares in hepatitis B e antigen-negative patients.","volume":"21","author":"Liu","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"jrv260008r58","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.cgh.2010.02.023","article-title":"Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B.","volume":"8","author":"Jeng","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"jrv260008r59","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/HEP.0000000000001107","article-title":"Finite nucleos(t)ide analog therapy for functional cure in HBeAg-negative chronic hepatitis B: recent development in the paradigm shift.","volume":"83","author":"Liaw","year":"2026","journal-title":"Hepatology"},{"issue":"2","key":"jrv260008r60","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B.","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"jrv260008r61","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jhep.2024.08.015","article-title":"Predictors of hepatic flares after nucleos(t)ide analogue cessation: results of a global cohort study (RETRACT-B study).","volume":"82","author":"Dongelmans","year":"2025","journal-title":"J Hepatol"},{"issue":"3","key":"jrv260008r62","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/apt.13272","article-title":"Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.","volume":"42","author":"Chang","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"jrv260008r63","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1016\/j.cgh.2024.05.040","article-title":"Stopping nucleos(t)ide analogues in chronic hepatitis B using HBsAg thresholds: a meta-analysis and meta-regression.","volume":"22","author":"Lim","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"jrv260008r64","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B Study).","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"issue":"26","key":"jrv260008r65","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv260008r66","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.","volume":"135","author":"Buster","year":"2008","journal-title":"Gastroenterology"},{"issue":"12","key":"jrv260008r67","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv260008r68","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1053\/j.gastro.2009.03.006","article-title":"Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.","volume":"136","author":"Marcellin","year":"2009","journal-title":"Gastroenterology"},{"issue":"6","key":"jrv260008r69","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","article-title":"Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.","volume":"137","author":"Buster","year":"2009","journal-title":"Gastroenterology"},{"issue":"3","key":"jrv260008r70","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/hep.26436","article-title":"Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.","volume":"58","author":"Sonneveld","year":"2013","journal-title":"Hepatology"},{"issue":"3","key":"jrv260008r71","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/0016-5085(95)90401-8","article-title":"Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus.","volume":"109","author":"Perrillo","year":"1995","journal-title":"Gastroenterology"},{"issue":"3","key":"jrv260008r72","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.","volume":"70","author":"Yip","year":"2019","journal-title":"J Hepatol"},{"issue":"1","key":"jrv260008r73","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis.","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"jrv260008r74","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B.","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"issue":"9865","key":"jrv260008r75","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"jrv260008r76","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.jhep.2020.01.007","article-title":"Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.","volume":"72","author":"Papatheodoridis","year":"2020","journal-title":"J Hepatol"},{"issue":"25","key":"jrv260008r77","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1056\/NEJMoa067710","article-title":"The HBV drug entecavir: effects on HIV-1 replication and resistance.","volume":"356","author":"McMahon","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv260008r78","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years of therapy.","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"jrv260008r79","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jhep.2009.11.007","article-title":"Efficacy of entecavir in treatment-na\u00efve patients with hepatitis B virus-related decompensated cirrhosis.","volume":"52","author":"Shim","year":"2010","journal-title":"J Hepatol"},{"issue":"1","key":"jrv260008r80","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/hep.23952","article-title":"Tenofovir disoproxil fumarate (TDF), emtricitabine\/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.","volume":"53","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"jrv260008r81","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1186\/s12879-025-11473-6","article-title":"Comparative effectiveness and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in patients with HBV-associated decompensated cirrhosis: insights from a retrospective analysis.","volume":"25","author":"Chen","year":"2025","journal-title":"BMC Infect Dis"},{"issue":"3","key":"jrv260008r82","doi-asserted-by":"publisher","first-page":"486","DOI":"10.14309\/ajg.0000000000002468","article-title":"Long-term treatment with tenofovir alafenamide for chronic hepatitis B results in high rates of viral suppression and favorable renal and bone safety.","volume":"119","author":"Chan","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"jrv260008r83","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/cid\/ciae288","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for preventing vertical transmission in chronic hepatitis B mothers: a systematic review and meta-analysis.","volume":"79","author":"Pan","year":"2024","journal-title":"Clin Infect Dis"},{"key":"jrv260008r84","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae479","article-title":"Primary care guidance for providers of care for persons with human immunodeficiency virus: 2024 update by the HIV Medicine Association of the Infectious Diseases Society of America.","author":"Horberg","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"9349","key":"jrv260008r85","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(02)11913-1","article-title":"HIV-1, hepatitis B virus, and risk of liver-related mortality in the multicenter cohort study (MACS).","volume":"360","author":"Thio","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"jrv260008r86","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals.","volume":"168","author":"Ali","year":"2025","journal-title":"Gastroenterology"},{"issue":"6","key":"jrv260008r87","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.jhep.2022.07.003","article-title":"Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: a systematic review, meta-analysis, and expert opinion.","volume":"77","author":"Papatheodoridis","year":"2022","journal-title":"J Hepatol"},{"issue":"6","key":"jrv260008r88","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma.","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"jrv260008r89","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"issue":"10","key":"jrv260008r90","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.7326\/M24-0384","article-title":"Viral load-based prediction of hepatocellular carcinoma risk in noncirrhotic patients with chronic hepatitis B: a multinational study for the development and external validation of a new prognostic model.","volume":"177","author":"Kim","year":"2024","journal-title":"Ann Intern Med"},{"issue":"3","key":"jrv260008r91","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/hep.1840080310","article-title":"The development of cirrhosis in patients with chronic type B hepatitis: a prospective study.","volume":"8","author":"Liaw","year":"1988","journal-title":"Hepatology"},{"issue":"2","key":"jrv260008r92","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jhep.2012.02.033","article-title":"Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy.","volume":"57","author":"Peng","year":"2012","journal-title":"J Hepatol"},{"issue":"9","key":"jrv260008r93","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/liv.13142","article-title":"Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis.","volume":"36","author":"Raffetti","year":"2016","journal-title":"Liver Int"},{"issue":"40","key":"jrv260008r94","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.3748\/wjg.v24.i40.4606","article-title":"Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis.","volume":"24","author":"Ju","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"3","key":"jrv260008r95","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cgh.2020.05.041","article-title":"Association between seroclearance of hepatitis b surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis.","volume":"19","author":"Anderson","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"jrv260008r96","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.jhep.2017.06.019","article-title":"Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.","volume":"67","author":"Yip","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"jrv260008r97","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jhep.2022.01.023","article-title":"HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis.","volume":"77","author":"Singal","year":"2022","journal-title":"J Hepatol"},{"issue":"4","key":"jrv260008r98","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/bjc.2016.422","article-title":"Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance.","volume":"116","author":"Johnson","year":"2017","journal-title":"Br J Cancer"},{"issue":"13","key":"jrv260008r99","doi-asserted-by":"publisher","first-page":"477","DOI":"10.15585\/mmwr.mm7113a1","article-title":"Universal hepatitis B vaccination in adults aged 19-59 years: updated recommendations of the Advisory Committee on Immunization Practices: United States, 2022.","volume":"71","author":"Weng","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"33","key":"jrv260008r102","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1016\/j.vaccine.2017.06.051","article-title":"Hepatitis B vaccine birth dose coverage correlates worldwide with rates of institutional deliveries and skilled attendance at birth.","volume":"35","author":"Allison","year":"2017","journal-title":"Vaccine"},{"issue":"27","key":"jrv260008r103","first-page":"369","article-title":"Hepatitis B vaccines: WHO position paper: July 2017.","volume":"92","author":"World Health Organization","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"issue":"1","key":"jrv260008r104","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.amepre.2023.01.041","article-title":"Gaps in prenatal hepatitis B screening and management of HBsAg positive pregnant persons in the US, 2015-2020.","volume":"65","author":"Pham","year":"2023","journal-title":"Am J Prev Med"},{"issue":"15","key":"jrv260008r105","doi-asserted-by":"publisher","first-page":"455","DOI":"10.15585\/mmwr.mm6715a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant.","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"jrv260008r106","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1001\/jama.2024.24490","article-title":"HepB-CpG vs HepB-alum vaccine in people with HIV and prior vaccine nonresponse: the BEe-HIVe randomized clinical trial.","volume":"333","author":"Marks","year":"2025","journal-title":"JAMA"},{"issue":"RR-10","key":"jrv260008r107","first-page":"1","article-title":"CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management.","volume":"62","author":"Schillie","year":"2013","journal-title":"MMWR Recomm Rep"},{"issue":"21","key":"jrv260008r108","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1016\/j.vaccine.2012.12.012","article-title":"Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review.","volume":"31","author":"Schillie","year":"2013","journal-title":"Vaccine"},{"issue":"4","key":"jrv260008r109","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/hep.32474","article-title":"Protection and antibody levels 35 years after primary series with hepatitis B vaccine and response to a booster dose.","volume":"76","author":"Bruce","year":"2022","journal-title":"Hepatology"},{"issue":"7","key":"jrv260008r110","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3390\/vaccines12070710","article-title":"A comprehensive review of hepatitis B vaccine nonresponse and associated risk factors.","volume":"12","author":"Tahir","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"jrv260008r111","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S1473-3099(20)30586-7","article-title":"Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis.","volume":"21","author":"Funk","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"jrv260008r112","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/oxfordjournals.aje.a112370","article-title":"The e antigen and vertical transmission of hepatitis B surface antigen.","volume":"105","author":"Beasley","year":"1977","journal-title":"Am J Epidemiol"},{"key":"jrv260008r4","unstructured":"Centers for Disease Control and Prevention. Table 2.3: acute hepatitis B: risk & exposure data. 2023 Viral Hepatitis Surveillance Report. Accessed March 9, 2026. https:\/\/www.cdc.gov\/hepatitis-surveillance-2023\/hepatitis-b\/table-2-3.html"},{"key":"jrv260008r5","unstructured":"World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries. Accessed March 11, 2026. https:\/\/iris.who.int\/bitstream\/handle\/10665\/376461\/9789240091672-eng.pdf"},{"key":"jrv260008r6","unstructured":"Centers for Disease Control and Prevention. Figure 2.1: acute hepatitis B: number of cases & estimated infections. Accessed March 9, 2026. https:\/\/www.cdc.gov\/hepatitis-surveillance-2023\/hepatitis-b\/figure-2-1.html"},{"key":"jrv260008r22","unstructured":"Centers for Disease Control and Prevention. Clinical testing and diagnosis for hepatitis B. Accessed March 11, 2026. https:\/\/www.cdc.gov\/hepatitis-b\/hcp\/diagnosis-testing\/index.html"},{"key":"jrv260008r40","unstructured":"Centers for Disease Control and Prevention. Clinical overview of hepatitis B. Accessed January 8, 2026. https:\/\/www.cdc.gov\/hepatitis-b\/hcp\/clinical-overview\/index.html"},{"key":"jrv260008r45","unstructured":"World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Accessed June 15, 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240090903"},{"key":"jrv260008r100","unstructured":"Centers for Disease Control and Prevention. Hepatitis B vaccine administration. Accessed March 10, 2026. https:\/\/www.cdc.gov\/hepatitis-b\/hcp\/vaccine-administration\/index.html"},{"key":"jrv260008r101","unstructured":"World Health Organization. Hepatitis B vaccination coverage. Accessed October 27, 2025. https:\/\/immunizationdata.who.int\/global\/wiise-detail-page\/hepatitis-b-vaccination-coverage"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2848693\/jama_jeng_2026_rv_260008_1779390013.46955.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:00:46Z","timestamp":1780412446000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2848693"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":112,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026,6,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2026.6070","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,2]]}}}